Ryan Haumschild, PharmD, MBA
Articles by Ryan Haumschild, PharmD, MBA

Guidelines, Infrastructure, and Stakeholder Roles in Biomarker Testing for Extrapulmonary Neuroendocrine Carcinoma
ByRyan Haumschild, PharmD, MBA,William K. Oh, MD,Aman Chauhan, MD,Namrata Vijayvergia, MD,Sandy Kotiah, MD Experts explain evolving biomarker testing for rare neuroendocrine carcinomas, from NCCN gaps to DLL3 and NGS, guiding trials and treatment.

Current Treatments and Biomarker Testing in Extrapulmonary Neuroendocrine Carcinoma: Strengths, Limitations, and Clinical Relevance
ByRyan Haumschild, PharmD, MBA,William K. Oh, MD,Aman Chauhan, MD,Namrata Vijayvergia, MD,Sandy Kotiah, MD Learn how aggressive neuroendocrine carcinoma disrupts daily life—and why rapid treatment, strong caregiver support, and navigation resources matter.

Navigating the Human Side of Extrapulmonary Neuroendocrine Carcinoma: Patient Burden and Caregiver Support
ByRyan Haumschild, PharmD, MBA,William K. Oh, MD,Aman Chauhan, MD,Namrata Vijayvergia, MD,Sandy Kotiah, MD Experts warn extrapulmonary neuroendocrine carcinomas are often missed; faster pathology, rapid referrals, and early treatment improve survival.

Closing the Gap: Underrecognition and the Critical Need for Early Diagnosis in Extrapulmonary Neuroendocrine Carcinoma
ByRyan Haumschild, PharmD, MBA,William K. Oh, MD,Aman Chauhan, MD,Namrata Vijayvergia, MD,Sandy Kotiah, MD Rare neuroendocrine carcinomas outside the lung often go missed; expert pathology and rapid referrals enable earlier treatment and better outcomes.

The Diagnostic Journey in Extrapulmonary Neuroendocrine Carcinoma: Team-Based Care and Classification
ByRyan Haumschild, PharmD, MBA,William K. Oh, MD,Aman Chauhan, MD,Namrata Vijayvergia, MD,Sandy Kotiah, MD Learn how rare neuroendocrine cancers are diagnosed, why pathology and Ki-67 guide care, and how teams coordinate chemo, trials, support.

Understanding Neuroendocrine Carcinomas: Definitions, Types, and Clinical Presentation
ByRyan Haumschild, PharmD, MBA,William K. Oh, MD,Aman Chauhan, MD,Namrata Vijayvergia, MD,Sandy Kotiah, MD Experts unpack neuroendocrine carcinoma vs tumors, key pathology markers, and high-risk features shaping prognosis and treatment decisions.